GANYMED PHARMACEUTICALS AG
Patent Owner
Stats
- 34 US PATENTS IN FORCE
- 3 US APPLICATIONS PENDING
- Mar 20, 2018 most recent publication
Details
- 34 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 974 Total Citation Count
- Jul 26, 2000 Earliest Filing
- 14 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0240,646 GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOFMar 03, 17Aug 24, 17[C07K]
2016/0339,101 COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCERAug 08, 16Nov 24, 16[A61K, C07K]
2015/0197,576 Identification of Tumor-Associated Antigens for Diagnosis and TherapyJan 27, 15Jul 16, 15[C07K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9919036 Identification of tumor-associated antigens for diagnosis and therapyJan 27, 15Mar 20, 18[A61K, C12Q, G01N, C07K]
9902778 Cancer therapy using CLDN6 target-directed antibodies in vivoJul 08, 16Feb 27, 18[A61K, C07K]
9775785 Antibody to genetic products differentially expressed in tumors and the use thereofApr 01, 15Oct 03, 17[A61K, C12N, G01N, C07K]
9770487 Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinomaFeb 18, 14Sep 26, 17[A61K, C07K]
9751934 Monoclonal antibodies against claudin-18 for treatment of cancerMar 18, 15Sep 05, 17[A61K, C07K]
9733251 Identification of tumour-associated cell surface antigens for diagnosis and therapySep 09, 15Aug 15, 17[A61K, C12Q, G01N, C07K]
9718886 Cancer therapy using CLDN6 target-directed antibodies in vivoJul 04, 11Aug 01, 17[A61K, C07K]
9637548 Methods and compositions for diagnosis and treatment of cancerFeb 18, 10May 02, 17[A61K, G01N, C07K]
9499609 Monoclonal antibodies against claudin-18 for treatment of cancerNov 29, 11Nov 22, 16[A61K, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0337,052 Genetic Products Differentially Expressed In Tumors And The Use ThereofAbandonedAug 07, 15Nov 26, 15[C07K]
2015/0132,253 COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCERAbandonedMay 21, 13May 14, 15[A61K, C07K]
2014/0199,762 Immunotherapeutic Methods Using Epitopes of WT-1 and GATA-1AbandonedAug 14, 13Jul 17, 14[C07K]
2014/0186,338 Genetic Products Differentially Expressed In Tumors And The Use ThereofAbandonedOct 01, 13Jul 03, 14[A61K, C07K]
8529904 Immunotherapeutic methods using epitopes of WT-1 and GATA-1ExpiredJul 06, 07Sep 10, 13[A61K, C07K]
8399210 Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseasesExpiredApr 08, 09Mar 19, 13[G01N]
2012/0165,390 Compositions and Methods for Therapy and Diagnosis of CancerAbandonedNov 21, 11Jun 28, 12[A61K, C12Q, C12N, G01N, A61P]
2012/0070,430 IDENTIFICATION OF TUMOR-ASSOCIATED MARKERS FOR DIAGNOSIS AND THERAPYAbandonedApr 22, 10Mar 22, 12[A61K, C07H, C12Q, C12N, G01N, A61P, C07K]
8088913 Compositions and methods for therapy and diagnosis of cancerExpiredDec 07, 06Jan 03, 12[C07H, A61K, C12N]
2011/0135,640 IDENTIFICATION OF TUMOUR-ASSOCIATED CELL SURFACE ANTIGENS FOR DIAGNOSIS AND THERAPYAbandonedDec 16, 10Jun 09, 11[A61K, C07H, C12Q, G01N, A61P, C07K]
2009/0253,775 Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer MetastasisAbandonedApr 08, 09Oct 08, 09[A61K, C12Q, G01N, A61P]
2009/0202,530 Identification of Tumor-Associated Antigens for Diagnosis and TherapyAbandonedSep 06, 06Aug 13, 09[A61K, C12Q, C12N, G01N, C07K]
2009/0081,214 GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOFAbandonedAug 25, 08Mar 26, 09[A61K, A61P]
7326767 Immunotherapeutic methods using epitopes of WT-1 and GATA-1ExpiredJul 26, 00Feb 05, 08[C07K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.